Researcher
Hannelore Denys
- Keywords:Clinical trials, Fundamental and translational research, Uterine cancer, cervical cancer, Breast cancer, Ovarian cancer
- Disciplines:Cancer diagnosis, Cancer epidemiology, Oncology not elsewhere classified, Cancer therapy, Cancer biology
Affiliations
- Board of Governors/Executive Board (Administrative office)
Member
From1 Oct 2022 → Today - Department of Internal Medicine and Pediatrics (Department)
Member
From1 Oct 2018 → Today - Department of Internal medicine (Department)
Member
From1 Oct 2011 → 30 Sep 2018
Projects
1 - 10 of 11
- Chitinase 3-like 1 as novel immunotherapeutic target in triple-negative breast cancerFrom1 Oct 2021 → TodayFunding: FWO junior postdoctoral fellowship
- PRIMMO trial - Extracellular vesicles to predict response to checkpoint inhibitors in cervical and endometrial cancer patientsFrom1 Jan 2021 → 31 Dec 2021Funding: Nonprofit institution or equivalents
- Analyzing circulating bacterial extracellular vesicles in cancer patients to identify their composition and biomarker potential.From1 Nov 2020 → 31 Mar 2023Funding: FWO fellowships
- Preclinical validation of novel anti-EMT therapy for malignant triple negative breast cancerFrom1 Mar 2020 → TodayFunding: Nonprofit institution or equivalents
- EV-TRACE: Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stageFrom1 Jan 2020 → 31 Dec 2023Funding: FWO Strategic Basic Research (SBO)
- Heading towards an in vivo predictive test for personalized ovarian cancer treatment: application of novel therapies in zebrafish patient derived xenograftsFrom1 Nov 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Impact of vaginal morbidity on sexual functioning in cervical cancer patients treated with neo-adjuvant chemotherapy followed by surgery.From1 Jan 2019 → 31 Dec 2020Funding: FWO research project (including WEAVE projects)
- beurs EVDS Sofie Van Dorpe: Extracellular vesicles as blood-based biomarker for early stage ovarian cancerFrom1 Oct 2018 → 30 Sep 2019Funding: Foundations, funds and other with scientific goal
- Targeting cancer-associated fibroblasts to overcome immunosuppressive mechanisms in mismatch repair-deficient tumorsFrom1 Oct 2018 → 30 Sep 2022Funding: FWO fellowships
- Combination of radiotherapy, PD-1 blockade and an immune-modulatory cocktail to combat cervical and uterine cancerFrom1 Jan 2017 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
Publications
1 - 10 of 125
- Endometrial carcinosarcoma(2023)
Authors: G Bogani, I Ray-Coquard, N Concin, NYL Ngoi, P Morice, G Caruso, T Enomoto, K Takehara, Hannelore Denys, D Lorusso, et al.
Pages: 147 - 174 - Completion surgery after intensity-modulated arc therapy for locally advanced cervical cancer : long-term follow-up and update on surgical outcome and oncologic results of a unique tertiary care single-center retrospective cohort(2023)
Authors: Axel Van Damme, Julie Rombaut, Amin Makar, Emiel De Jaeghere, Eline Naert, Hannelore Denys, Philippe Tummers, Katrien Vandecasteele
- Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer(2023)
Authors: Menekse GOKER, Hannelore Denys, An Hendrix, Olivier De Wever, Koen Van de Vijver, Geert Braems
- A preclinical platform for assessing long-term drug efficacy exploiting mechanically tunable scaffolds colonized by a three-dimensional tumor microenvironment(2023)
Authors: Elly De Vlieghere, Koen Van de Vijver, Eva Blondeel, Nathan Carpentier, Rouba Ghobeira, Jarne Pauwels, Sebastian Riemann, Manon Minsart, Charlotte Fieuws, Johanna Mestach, et al.
- Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma : results of the phase II PRIMMO study(2023)
Authors: Emiel De Jaeghere, Sandra Tuyaerts, An M. T. Van Nuffel, Ann Belmans, Kris Bogaerts, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.
Pages: 475 - 491 - Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression : results from the SORAYA study(2023)
Authors: UA Matulonis, D Lorusso, A Oaknin, S Pignata, A Dean, Hannelore Denys, N Colombo, T Van Gorp, JA Konner, MR Marin, et al.
Pages: 2436 - 2445 - Tumor-infiltrating lymphocytes and PD-L1 expression in pleomorphic lobular breast carcinoma(2023)
Authors: Menekse GOKER, Stephanie Deblaere, Hannelore Denys, Glenn Vergauwen, Eline Naert, Rudy Van den Broecke
- Integrating automated liquid handling in the separation workflow of extracellular vesicles enhances specificity and reproducibility(2023)
Authors: Sofie Van Dorpe, Lien Lippens, Robin Boiy, Cláudio Pinheiro, Glenn Vergauwen, Pekka Rappu, Ilkka Miinalainen, Philippe Tummers, Hannelore Denys, Olivier De Wever, et al.
- Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose : a retrospective cohort study(2023)
Authors: Koen Kortbeek, Sigurd Delanghe, Sylvie Rottey, Hannelore Denys, Lore Lapeire
Pages: 298 - 307 - Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer : a Belgian expert opinion(2022)
Authors: I Vergote, Hannelore Denys, S. Altintas, J. Kerger, J-F Baurain, V Bours, S. Henry, Koen Van de Vijver, D. Lambrechts, C. Gennigens
Pages: 111 - 120